Rx Rundown: Vertex Pharmaceuticals, Bristol Myers Squibb, Novartis and more mmm-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mmm-online.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that the Food and Drug Administration has accepted and granted Priority Review to the supplemental Biologics License Application or sBLA for ENHERTU (fam-trastuzumab deruxtecan-nxki) in the US for patients with metastatic HER2-positive solid tumors.